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Existing CB1 negative allosteric modulators (NAMs) fall into a limited range of structural 
classes.  In spite of the theoretical potential of CB1 NAMs, published in vivo studies have 
generally not been able to demonstrate the expected therapeutically-relevant CB1-mediated 
effects. Thus, a greater range of molecular tools are required to allow definitive elucidation of 
the effects of CB1 allosteric modulation.  In this study, we show a novel series of indole 
sulfonamides.  Compounds 5e and 6c (ABD1075) had potencies of 4 and 3 nM respectively, and 
showed good oral exposure and CNS penetration, making them highly versatile tools for 
investigating the therapeutic potential of allosteric modulation of the cannabinoid system.  
2009 Elsevier Ltd. All rights reserved. 
 
Keywords: 
Cannabinoid  
Negative allosteric modulator 
CB1 NAM 
Indole sulfonamide 
  
Drugs which block cannabinoid receptor activation were 
expected to find a huge market for the treatment of obesity, 
addiction and metabolic syndromes (e.g. type-2 diabetes).  
However, rejection by the FDA and eventual withdrawal in 
Europe of the first such drug to reach the market (rimonabant) 
effectively terminated this line of approach, in spite of the 
apparent therapeutic utility.
1
 There are a number of different 
approaches now being taken to harness the potential of the 
cannabinoid system, whilst avoiding the side-effects of previous 
approaches that entailed global antagonism.
2
 Such approaches 
include the use of neutral antagonists, negative allosteric 
modulators and peripheral restriction.
1,2
 
CB1 receptors and endocannabinoids are present in peripheral 
tissues involved in metabolic dysfunction associated with 
obesity, including adipose tissue, liver, skeletal muscle and 
pancreas, and there is evidence for the upregulation of the 
endocannabinoid system in these tissues in experimental and 
human obesity.
3
 Activation of CB1 receptors in peripheral tissues 
promotes lipogenesis, lipid storage, insulin secretion, glucagon 
secretion and adiponectin modulation.
4-6
 Furthermore, a 
peripherally-restricted CB1 receptor antagonist does not affect 
behavioural responses in mice with genetic or diet-induced 
obesity, but it does cause weight-independent improvements in 
glucose homeostasis, fatty liver, and plasma lipid profile.
7
 These 
findings confirm a prominent role for peripheral CB1 receptors 
on the modulation of metabolism and the potential for therapeutic 
benefit in the absence of CNS-mediated side-effects.
1
 
Allosteric modulators  are playing an increasingly prominent 
role in therapeutics, having the advantage of more subtle 
modulation of receptor activity than intervention at the 
orthosteric site, the normal binding site for the endogenous ligand 
Furthermore, the allosteric sites of many receptors offer greater 
opportunities for selectivity, whereas the orthosteric sites of 
many receptors and subtypes can be too similar to allow a drug to 
distinguish between them, as they often must bind the same 
endogenous ligand.
8
 In 2005, the first evidence was published 
indicating that the cannabinoid CB1 receptor contains an 
allosteric binding site and compounds such as Org27569 were 
identified that unexpectedly were allosteric enhancers of agonist 
binding affinity, but functionally were allosteric inhibitors of 
agonist signalling efficacy.
9
 Related analogues of Org27569
10-14
 
and the diphenylurea PSNCBAM-1
15
 were subsequently found to 
display similar pharmacological profiles. Org27569 and 
analogues have been widely studied and photo-activated 
derivatives of Org27569 have been highly effective for mapping 
of the CB1 allosteric binding site.
16,17
  However, in vivo studies 
using Org27569 gave unexpected results: Org27569 did not 
modulate agonist-induced catalepsy or nociception,
18,19
 though it 
did antagonize reinstatement of extinguished cocaine and 
methamphetamine seeking behaviours,
20
 and showed conflicting 
effects on agonist-induced hypothermia.
18,19
  Thus, both Gamage 
et al. and Ding et al. have been led to conclude that Org27569 
does not function as a CB1 NAM in vivo and is acting by non-
CB1 mediated mechanisms.
18,19
    
In view of these unexpected results, it is clear that a wider 
range of potent tool compounds is required in order to provide 
more definitive evaluation of the effects of CB1 allosteric 
modulation and therapeutic potential  Our studies focused on 
bioisosteric replacement of the amide bond in Org27569 (Figure 
1) with a sulfonamide, with the expectation of increasing 
metabolic stability and perhaps giving access to a greater range 
of structural motifs, and consequently better control of 
physiochemical properties than is afforded by the limited range 
of existing compounds: for example, the preparation of highly-
polar peripherally-restricted structures.  
 
Figure 1. Structure of Org27569 
 
 We set about synthesising a range of sulfonamide analogues 
of Org27569, using the methodology shown in Scheme 1.
21
 
Substituted indoles were commercially-available or prepared as 
described previously.
22
 The indole products were N-protected, 
deprotonated at the 2-position with n-butyllithium in THF, and 
reacted with sulfur dioxide to give the corresponding lithium 
sulfinates. Reaction with N-chlorosuccinimide in DCM gave the 
corresponding sulfonyl chlorides, which were subsequently 
coupled with the amine of choice and N-deprotected (to generate 
compounds 1a – 1w, 2a, 2b, 2t and 2u) or with the required 4-
bromobenzylamine, N-deprotected, and further Suzuki coupling 
performed (to give compounds 2c – 2u and 2v – 2z). 
Scheme 1. Synthesis of indole-2-sulfonamides 2a – 2z: Reagents and 
conditions (a) 2-oxovaleric acid PTSA, EtOH (reflux, 20 h); (b) 5% NaOH, 
EtOH (40
 o
C, overnight); (c) Cu, quinoline (microwaved for 25 min at 250 
0
C); (d) NaH, BzSO2Cl, DMF (rt, 18 h); (e) 1.6 M n-BuLi, THF, SO2, (-78 ºC 
to rt, 2 h); (f) NCS, DCM (0 ºC to rt, 2 h); (g) 4-bromobenzylamine, pyridine, 
DCM (0 ºC to rt, 18 h); (h) 10 % NaOH, EtOH, (reflux, 2 h); (i) substituted 
benzeneboronic acid, (PPh3)4Pd, ethanol, toluene, 2 M Na2CO3, (reflux, 3 h). 
 
Initial studies, on compounds closely related to Org27569, 
suggested that the sulfonamide analogues were around 100-fold 
less potent than their amide counterparts and had very low 
metabolic stability, and thus were of limited developmental value 
(Table 1 and Table 3). However, a breakthough in potency was 
seen when 4-phenylbenzylamine was used as the side chain, 
giving compounds 2a and 2b, with IC50 values of 8 and 2 nM 
respectively in the PathHunter hCB1 β-Arrestin assay,
12
 
comparable to that of Org27569 (Figure 2, Tables 1 - 3).  
 
 
  
 
Figure 2. Allosteric modulation by 2c in PathHunter hCB1 β-Arrestin assay 
 
 
  
 
  
 
 
R1 R2 R3 n IC50, nM
a
 
Org27569  2 
1a Cl Et 4-(Piperidino)phenyl 2 120 
1b Cl Et 4-(Dimethylamino)phenyl 2 130 
1c H Me 4-(Piperidino)phenyl 2 200 
1d H Me 4-(Dimethylamino)phenyl 2 300 
1e Cl Et 4-(Morpholino)phenyl 2 500 
1f H Me 4-(Morpholino)phenyl 2 >1000 
1g H Me Phenyl 1 >1000 
1h H Me Phenyl 2 >1000 
1i H Me 4-Methylphenyl 1 200 
1j H Me 4-Methoxyphenyl 1 200 
1k H H 4-Methoxyphenyl 1 200 
1l H Me 4-Chlorophenyl 1 400 
1m OMe H 4-Methoxyphenyl 1 400 
1n Cl Me 4-Methoxyphenyl 1 500 
1o H Me 4-(Trifluoromethyl)phenyl 1 250 
1p H Me 3-Chlorophenyl 1 800 
1q H Me 3,4-Dichlorophenyl 1 800 
1r Cl Et 4-Chlorophenyl 1 >1000 
1s H Me 2-Pyridyl 1 >1000 
1t H Me 3-Pyridyl 1 >1000 
1u H Me Cyclohexyl 1 >1000 
1v H Me N-Morpholino 2 >1000 
1w H Me N-Morpholino 3 >1000 
Table 1. Structures and potencies of compounds 1a – 1w, aPotency in 
PathHunter™ hCB1 β-Arrestin assay (DiscoveRx, Fremont, USA) performed 
in triplicate.  
Additional substituents could be introduced on the outer 
phenyl ring by reacting the sulfonyl chloride with 4-
bromobenzylamine to give an intermediate that could be coupled 
with the required benzeneboronic acid by standard Suzuki 
coupling methods. This was used to give further potent 
compounds: 4’-fluoro, 4’-methoxy, 4’-dimethylamino and 4’-
methyl groups, all with potencies of <5 nM (compounds 2c – 2f, 
Table 2). Modifications to other parts of the structure gave a 
similarly flat SAR: 6-chloro, 5-bromo,  6-fluoro and 5-
methoxyindole derivatives all having very similar potencies 
(compounds 2g – 2i and 2p, Table 2). The use of indoles  bearing 
more polar substituents, including cyano and substituted amines 
(e.g. sulfonamides and amides, accessible via the nitroindole), 
was precluded by the reactivity of these groups to  butyllithium 
under these reaction conditions. 
As one of our aims was to make more polar compounds with 
no loss of potency, this insensitive SAR seemed ideal. However, 
very polar groups were not tolerated on the outer ring: addition of 
4’-carboxy or 3’-carboxamide groups (2j, and 2k, Table 2) gave 
poorly active compounds. Less polar substituents and 
arrangements such as 4’-methanesulfonyl, 4’-hydroxymethyl, 4’-
hydroxy-3’-methoxy, 4’cyano and 2,4-dimethoxy (2l – 2p), gave 
smaller losses in potency and demonstrated that some degree of 
polarity could be introduced here (most notably with a cyano 
group). 
 
 
R1 R2 R3 R4 R5 IC50, nM
a
 
2a H H Me H H 8 
2b H H H H H 2 
2c H H H H 4-F 1 
2d H H H H 4-OMe 2 
2e H H H H 4-NMe2 3 
2f H H H H 4-Me 3 
2g Br H H H H 6 
2h H F H H H 5 
2i H Cl H H H 4 
2j H H H H 4-CO2H >1000 
2k H H H H 3-CONH2 300 
2l H H H H 4-SO2Me 15 
2m H H H H 4-OH-3-OMe 33 
2n H H H H 2,4-OMe 22 
2o OMe H H H 4-CH2OH 112 
2p OMe H H H 4-CN 8 
2q Br H H H 4-F 12 
2r Cl H H H 2,4-FF 4 
2s Cl H H H 4-SO2Me 15 
2t H H CH2OMe H H 10 
2u H H CH2OH H H 12 
2v Cl H H 2-F 4-F 21 
2w OMe H H 2-F OCF3 40 
2x Cl H H 2-Me 4-F >1000 
2y Cl H H 3-Me 4-F >1000 
2z H H H (thiophen-3-yl)phenyl 12 
Table 2. Structures of compounds and potencies of compounds 2a – 2z. 
a
Potency in PathHunter™ hCB1 β-Arrestin assay (DiscoveRx, Fremont, 
USA) performed in triplicate.   
Modifications at position-3 of the indole were also 
investigated. Addition of a hydroxymethyl group at position-3 
was considered as a promising means by which polarity might be 
increased. The expected route to introduction of a hydroxymethyl 
was via Vilsmeier-Haack formylation of the relevant final 
compound or its 1-N-benzenesulfonyl-protected precursor.  
However, we were not able to optimise the reaction conditions 
and either the reaction did not occur or multiple products were 
obtained.  Instead we found it necessary to introduce the 
hydroxymethyl prior to sulfonylation.  This could be achieved 
from reduction of the indole-3-carboxaldehyde to give the 
alcohol (see Suppprting Information).  The alcohol was protected 
with a tert-butyldimethylsilyl group and scheme 1 followed to 
give compound 2u, which showed only a small reduction in 
potency (IC50 = 12 nM). Addition of a methoxymethyl group at 
position-3 was also a promising means to increase polarity.  This 
could be achieved via the required gramine derivative (indol-3-
yl-N,N-dimethylmethanamine, see Supporting Information).  The 
3-CH2NMe2 group was introduced by a Mannich amination,
23
 
and then converted into the 3-methoxymethyl derivative by 
reaction with methyliodide in the presence of sodium 
methoxide.
24
 The 3-methoxymethylindole was then sulfonylated 
as described in scheme 1, to give compound 2t, which again 
showed only a small reduction in potency (IC50 = 10 nM). Thus 
  
the nature of the 3-substituent appeared to have little impact, with 
H, Me, CH2OMe and CH2OH all showing similar potencies 
(compounds 2a, 2b, 2t and 2u, Table 2). 
Stability studies in human liver microsomes (HLM) gave 
disappointing results: compounds 2c, 2g and 2i were metabolised 
very rapidly (T½ <15 min, Table 3), apparently by ring 
oxidation, suggesting that at least two of the aromatic rings 
needed to be protected. The electron-donating influence of the 
amine on the inner ring of the biphenyl made it also seem a likely 
candidate for metabolism. Reduction of electron density on this 
ring, via addition of electron-withdrawing groups on the adjacent 
outer ring, was an effective strategy: compounds 2q and 2r, 
bearing two or three strongly electron-withdrawing groups, a 5-
bromo or 5-chloro on the indole and a 4’-fluoro or 2’,4’-difluoro 
on the biphenyl, both showed a promising improvement in 
stability (2r: T½ >110 min in the HLM assay).   
We also investigated the influence of substitution on the 
middle ring, both to block metabolism and for its affects on 
potency.  The required bromobenzylamine could be prepared by 
Suzuki coupling of the substituted 4-bromobenzonitrile with an 
appropriate benzeneboronic acid, and reduction with lithium 
aluminium hydride to give the substituted 4-phenylbenzylamine 
(see Supporting Information), and compounds 2v – 2y were 
prepared.  The methyl derivatives 2x and 2y showed a reduction 
in potency (IC50 = 1100 and 123 nM respectively), but 2v and 2w 
had reasonable potency (IC50 = 21 and 40 nM respectively); the 
addition of the fluoro group also had the effect of blocking 
metabolism on the middle ring and compound 2v was stable in 
the HLM assay (T½ >140 min), either by blocking the site of 
metabolism or reducing electron density to make the ring less 
susceptible to metabolism.  Replacement of the 5-chloro with a 
5-methoxy, in an effort to increase polarity, gave compounds 
with reduced metabolic stability (2p and 2w). Replacement of the 
outer phenyl with a 3-thiophene, a common bioisteric 
replacement, gave only a small loss of potency (compound 2z).  
Further modifications were made to the structure, including 
addition of an α-methyl onto the benzylamine side chain and 
changing the connectivity of the biphenylamine (compounds 3 
and 4 respectively, Figure 3), using commercially-available α-
methyl-4-bromobenzylamine and 3-bromobenzylamine 
respectively; both additions gave reductions in potency (IC50 = 41 
and 137 nM respectively).   
Figure 3. Structures of compounds 3 and 4 
Derivatives bearing an outer-ring pyridine (Figure 4) could be 
prepared by the same methodology as shown in scheme 1 
followed by Suzuki coupling of the 4-bromobenzyl intermediate 
with a suitable pyridylboronic acid as the final step.  The 
unsubstitued 3-pyridyl derivative (5a) was found to be very 
unstable in the HLM assay, and we sought to place a 2-fluoro 
group (5b and 5c) or a 2,6-difluoro group (5e) on the pyridine to 
block metabolism.  All of the compounds showed excellent 
potency (IC50 <10 nM) but only 5e showed acceptable metabolic 
stability. Attempts to increase polarity by introduction of an 
amino group (5f) gave a reduction in potency to 85 nM.  
 
 
 
IC50, 
nM
a
 
HLM 
T1/2(min)
b
 
RLM 
T1/2(min)
b
 
Permeability 
Papp(cm
-6
/s)
c
 
TPSA 
(A
2
) 
Brain : 
Blood 
Org27569 2 32 28 1.23 44 1.1
19
 
1a 120 14 - - - - 
1d 300 13 - - - - 
1e 500 10 - - - - 
1h 200 3 - - - - 
1i 200 7 - - - - 
1k 400 2 - - - - 
2c 1 - <15 - 58 - 
2g 6 - <15 - 58 - 
2i 4 - <15 - 58 - 
2j >1000 - - - 96 - 
2k 300 - - - 101 - 
2p 8 - 26 - 91 - 
2q 12 - 130 - 58 - 
2r 4 111 84 - 58 - 
2s 15 41 36 - 92 - 
2v 21 146 112 - 78 - 
2w 40 - <15 - 58 - 
5a 7 - <15 - 71 - 
5b 3 <15 <15 - 80 - 
5c 5 22 23 - 71 2.7
d
 
5d 10 - - - 80 - 
5e 4 39 48 141 71 0.8
d
 
5f 85 - - - 97 - 
6a 9 - 25 - 71 - 
6b 4 53 33 - 71 - 
6c 3 56 32 53.8 71 3.3
d
 
Table 3. In vitro potency, pharmacokinetic and physiocochemical properties 
of selected compounds, 
a
Potency in PathHunter™ β-Arrestin assay 
(DiscoveRx, Fremont, USA) performed in triplicate, 
b
human and rat liver 
microsomal stability assays conducted by Cyprotex Ltd and performed in 
triplicate, 
c
PAMPA assay conducted by Cyprotex Ltd and performed in 
triplicate. 
d
Brain penetration studies conducted by the Dundee Drug 
Discovery Unit, in female NMRI mouse and performed in triplicate and 
samples taken at Tmax (T = 2 h for 5c and 6c; 4 h for 5e). 
 
Figure 4. Structures of compounds 5a – 5f 
Compounds with a pyridyl middle ring (Figure 5) could be 
prepared by Suzuki coupling of 5-bromo-2-pyridinecarbonitrile 
with the appropriate benzeneboronic acid and subsequent 
reduction with LiAlH4 at low temperatures. The resultant (5-
(phenyl)pyridin-2-yl)methanamine could be coupled with the 
indole-2-sulfonyl choride in THF in the presence of a 
stoichiometric quantity of DMAP (see Supporting Information).  
Compound 6a was prepared by this method and found to be 
highly potent (IC50 = 9 nM); however it showed only modest 
stability in mouse liver microsomes (T½ = 25 min). As the 2,4-
difluorophenyl had previously been found to stabilise a middle-
ring phenyl (2r), it was hoped that it might also stabilise a 
middle-ring pyridyl, and compounds 6b and 6c were prepared.  
These were found to be highly potent (IC50 = 4 and 3 nM 
respectively), to have good stability in human liver microsomes 
(T½ = 53 and 56 min respectively) and reasonable stability in rat 
liver microsomes (T½ = 33 and 32 min respectively). 
  
Figure 5. Structures of compounds 6a – 6c bearing a middle ring pyridine 
 
Table 3 demonstrates that it is possible to generate derivatives 
with fairly high TPSA with no loss of potency. Compounds 2p 
and 2s both have TPSA of >90 Å
2
, which is above the threshold 
for passive CNS penetration suggested in most studies.
25
 
However, it was not possible to achieve significantly higher 
TPSA while retaining stability and potency. Unexpectedly, whilst 
compounds 5e and 6c both have significantly higher TPSA than 
Org27569, the also have a much higher in vitro permeability than 
Org27569 (Table 3), whilst at the same time retaining similar in 
vivo brain penetration. In spite of predicted low permeability, and 
anticipated poor stability caused by the central amide group, 
Org27569 has in fact been shown to have both excellent brain 
penetration and stability.
19
  It is not understood as to why there is 
little or no in vitro : in vivo correlation in this case. Thus, for 
these compounds it is not clear that we will be able to predict or 
achieve peripheral restriction.    
Having the best balance of properties, compounds 5e 
(ABD1085
26
) and 6c (ABD1075
26
) were selected for further PK 
evaluation. Both compounds showed acceptable mouse oral 
exposure and in vivo stability (10 mg/kg oral, female NMRI, N = 
3). 5e: Blood Cmax = 672 ng/mL, Tmax = 4 h, T½ = 7.9 h AUC0-8 = 
263 µg/mL*min.  6c: Blood Cmax = 848 ng/mL, Tmax = 1 h, T½ = 
3 h, AUC0-8 =282 µg/mL*min.  
In conclusion, we have demonstrated a novel class of highly 
potent CB1 negative allosteric modulators with excellent 
metabolic stability and membrane permeability. These show a 
wide scope for variation of physicochemical parameters whilst 
retaining potency. Thus, these may provide highly-versatile tools 
for investigating the therapeutic potential of the cannabinoid 
system. 
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